z-logo
open-access-imgOpen Access
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy
Author(s) -
Ting Huang,
Huiqiang Wang,
Nanhai G. Chen,
Alexa Frentzen,
Boris Minev,
Aladar A. Szalay
Publication year - 2015
Publication title -
molecular therapy — oncolytics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.424
H-Index - 23
ISSN - 2372-7705
DOI - 10.1038/mto.2015.3
Subject(s) - oncolytic virus , cancer research , vaccinia , virotherapy , angiogenesis , tumor progression , tumor microenvironment , vascular endothelial growth factor , biology , antibody , cancer , epidermal growth factor , immunology , virus , receptor , tumor cells , vegf receptors , biochemistry , gene , recombinant dna , genetics
The tumor microenvironment plays an important role in tumor growth and progression. Here we demonstrate that vaccinia virus-mediated, constitutively expressed intratumoral antibodies against vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and fibroblast activation protein (FAP) significantly improved tumor regression and oncolytic virotherapy through suppression of angiogenesis, cell proliferation, and stromagenesis in virus-colonized tumors. In contrast to the tumor growth inhibition by the three tumor growth-inhibiting antibodies individually, when two of the three antibodies were expressed simultaneously by single vaccinia virus strains tumor regression was further enhanced. These findings strongly indicate that interference with the two tumor growth-stimulating mechanisms did in fact result in enhanced therapeutic efficacy in tumor xenograft models and may lead to an effective therapy in patients with cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom